Member Info for beinthelead

Was thinking that earlier. He’s missed out the troll rich period.

Madness. It’s clear that first mover advantage was in play, plus the scale at which they can deliver. I think this was the deciding factor. Huge, huge numbers required for mass testing.

Green light devices required going forward. Only the best will out.

Be nice to us helping them out in the near future. Market wide open as the spotlight is now on white label tests. The ‘Wild West’ diagnostics industry might just be moving into a phase of regulation.

Ndn - stop being so emotional. It’ll make you bitter.

You are a raving lunatic. Proper mad. You’re having conversation with yourself on here this morning when you don’t get any attention.

I top up when cash flow arrives. You know, when you get paid??

You sit on here an Twitter (Egbert) insulting people. Psychotic to say the least.

Ndn - stop attention seeking. Your post will get the value it deserves.

If you invest in a company, it lasts longer than weeks. You pick your entry based on an opportunity to make a profit.

If you have invested in a high risk biotech in the last couple of months - have some patience.

It’s cat and mouse. We’ve had fantastic stability through the delays and CE c0ck ups, where the market could/should have punished us. No more reasons (reported) for the delay, hence the drift being more concentrated.

The market is always right. I’m comfortable with how the market is viewing us, as it’s objectively fair. The rerate to come is based on numbers, not sentiment, hence it doesn’t really matter where we are when it lands. No more hiding places - R&D done, time to deliver :)

Buying more.

Spot on.

Based on them being used at 5m/week? My word.

Why are you invested then? By that logic we’re not selling a test in the UK.

SureScreen are building a huge facility in the UK
Innova are building a huge facility in the UK
ABDX are expanding
ODX have expanded (by proxy)

That signals demand outside of the current Innova stockpile you state.

Stats don’t drive the requirement at all. False statement.

We were developing a saliva test year so access to the required market would have been miraculous. We have the best test available to buy right now, but we’re not selling. My guess is the capacity (all tests we can currently make) are allocated to HMG.

Mental. Watch the pivot on orders.

Thanks tecbadger.

The point I’m making is similar to Ndn’s - marketed tests aren’t validated using 1000’s of samples in the real world. It’s not possible.

Our validation process is benchmarked using the same criteria as other, PCR Ct. that’s the best we can do. Therefore, it matters not.

Statically significant for what?

We need to get out of the weeds here. We have a best in class test that is CE marked and registered with the MHRA for sale in the UK.

AS has confirmed that the only revenue stream in the UK is via HMG. Simple as that. Does this mean we’re selling to them? It’s certainly a big hint.

Templar - your industry is admirable, but regurgitating RNS’s is not helping.

We were going to fly when 241 was broken...

The only truth in reading the charts is the support. We trade in zones buffered by them with no news. The rise/fall is commensurate with the news. Not the trend line/or mystic forecast.

They will have done PL. Pure madness. I’m far less annoyed by the critics. At least they have a purpose.

People will have lost a fortune with your sermons. They’re as welcomed as the constant noise from the subtle domesday prophets.

They couldn’t energy. The test performance figures are quoted based on the results across the measured range, during CV. The RNS was correct, and they will no doubt quote this during comms and PR push.

What a twine. If you knew, you should have sold first thing.